Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novocure Ltd Ord Sh (NQ: NVCR )

74.70 +0.65 (+0.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 588,525
Open 75.57
Bid (Size) 74.70 (5)
Ask (Size) 74.76 (27)
Prev. Close 74.05
Today's Range 70.32 - 76.98
52wk Range 56.51 - 232.76
Shares Outstanding 103,647,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2022
Upgrades 
Via Benzinga
NovoCure: Q1 Earnings Insights
NovoCure (NASDAQ:NVCR) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-6.74%
-6.74%
1 Month
-10.70%
-10.70%
3 Month
-3.97%
-3.97%
6 Month
-23.00%
-23.00%
1 Year
-58.70%
-58.70%

More News

Read More
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Via Benzinga
Novocure's TTFields Show Improved Progression-Free, Overall Survival Over Matched-Control
Via Benzinga
Where NovoCure Stands With Analysts
Via Benzinga
Novocure Reports First Quarter 2022 Financial Results
From Novocure
Via Business Wire
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
From Novocure
Via Business Wire
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields
From Novocure
Via Business Wire
Novocure to Report First Quarter 2022 Financial Results
From Novocure
Via Business Wire
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
Via Benzinga
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial
From Novocure
Via Business Wire
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer
From Novocure
Via Business Wire
Up On Bad News
Via Talk Markets
Lucky Day
Via Talk Markets
World Markets News For Friday
Via Talk Markets
Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation
From Novocure
Via Business Wire
Novocure’s General Counsel Resigns After 10 Years of Service
From Novocure
Via Business Wire
Novocure Q4 Earnings Miss Street View, New Data Shows TTFields Initiates Downstream Anti-Tumor Response
Via Benzinga
New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response
From Novocure
Via Business Wire
Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Bionano Stock Looks to Have a Monster Comeback in Its Future
Via InvestorPlace
Give peace a chance
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.